Theravance Biopharma, Inc.
TBPH
$8.62
$0.0250.29%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -56.42M | -49.40M | -45.65M | -44.77M | -55.19M |
| Total Depreciation and Amortization | 6.12M | 6.47M | 6.25M | 6.35M | 6.15M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 18.40M | 28.39M | 28.58M | 28.13M | 30.38M |
| Change in Net Operating Assets | 20.36M | 3.05M | 2.05M | -6.51M | -8.34M |
| Cash from Operations | -11.54M | -11.49M | -8.78M | -16.80M | -27.00M |
| Capital Expenditure | -332.00K | -819.00K | -825.00K | -1.64M | -2.49M |
| Sale of Property, Plant, and Equipment | -- | 0.00 | 0.00 | 1.30M | 1.51M |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 12.62M | -3.26M | 14.12M | 27.72M | -31.72M |
| Cash from Investing | 12.28M | -4.08M | 13.30M | 27.38M | -32.70M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 607.00K | 617.00K | 592.00K | 619.00K | 619.00K |
| Repurchase of Common Stock | -3.10M | -33.36M | -64.37M | -145.03M | -199.55M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -2.50M | -32.74M | -63.77M | -144.41M | -198.93M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.75M | -48.31M | -59.25M | -133.83M | -258.63M |